RDY — DR REDDYS LABORATORIES LTD

NYSE · Health Care · Pharmaceuticals · CIK 1135951 · India
Last close
$13.37
Market Cap
$11.13B
52W High
$14.61
52W Low
$12.19
ADV30
2,424,829
Next earnings
2026-07-23
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 75,162,000,000 43,035,000,000 829,000,000 2,209,000,000 579,346,000,000 15,368,000,000 198,889,000,000
Dec 2025 87,268,000,000 46,806,000,000 14,330,000,000 12,098,000,000 562,899,000,000 18,657,000,000 187,143,000,000
Sep 2025 88,051,000,000 48,140,000,000 17,867,000,000 14,372,000,000 542,005,000,000 9,906,000,000 179,923,000,000
Jun 2025 85,452,000,000 48,627,000,000 16,842,000,000 14,178,000,000 519,537,000,000 9,004,000,000 165,782,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$63,106,000,000
Investing CF
$-52,327,000,000
Financing CF
$-6,119,000,000
CapEx
$-38,848,000,000
Dividends Paid
$-6,659,000,000
Buybacks
EPS Diluted TTM
$67.89
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$349,783,000,000
Inventory
$79,009,000,000
Receivables
$124,269,000,000
ST Investments
$63,932,000,000
EBIT TTM
$76,217,000,000
Pretax Income TTM
$72,880,000,000
Interest Exp TTM
$3,337,000,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$335,933,014,016
EBITDA
$68,148,998,144
Free Cash Flow
$1,627,500,032
Enterprise Value
$58,888,110,080
Total Cash
$87,813,996,544
Total Debt
$77,340,999,680
Shares Out
832,703,495
Trailing EPS
$0.54
Book Value
$0.79
ROE
11.8%
ROA
5.7%
Div Yield
0.63%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 335,933,000,000 47,465,000,000 41,960,000,000 579,346,000,000 198,889,000,000 56,737,000,000
Mar 2025 325,535,000,000 72,014,000,000 56,544,000,000 492,989,000,000 155,823,000,000 46,428,000,000
Mar 2024 279,164,000,000 65,308,000,000 55,684,000,000 387,518,000,000 106,968,000,000 45,433,000,000
Mar 2023 245,879,000,000 59,054,000,000 45,067,000,000 321,854,000,000 90,863,000,000 58,875,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.67

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.50 · spot: $13.37 · call volume: 24 · put volume: 112
Expected Move to 2026-09-18: ±$1.51 (11.29%) — implied range $11.86$14.88 · ATM straddle on $12.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SMMT Summit Therapeutics Inc. $11.09B $14.29
BMRN BIOMARIN PHARMACEUTICAL INC $11.19B $57.91
MDGL MADRIGAL PHARMACEUTICALS, INC. $11.00B $476.89
ARWR ARROWHEAD PHARMACEUTICALS, INC. $10.33B $73.33
ELAN Elanco Animal Health Inc $12.24B $24.50

News headlines (Yahoo Finance, 1h cache)

Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
2026-06-08 14:43 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
2026-06-05 14:38 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
2026-06-01 14:40 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week
2026-05-29 14:40 · Yahoo
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
2026-05-29 12:55 · Yahoo
Asian Equities Traded in US as ADRs Fall in Wednesday Trading
2026-05-27 14:37 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
2026-05-26 14:41 · Yahoo
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
2026-05-16 07:18 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
2026-05-15 14:38 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
2026-05-14 14:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.